Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
- Matter-Walstra K University Basel, Basel, Switzerland. klazien.matter@unibas.ch.
- Schwenkglenks M University Basel, Basel, Switzerland.
- Dedes KJ Swiss Group of Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland.
- 2017-03-22
Published in:
- Breast cancer research and treatment. - 2017
Breast Neoplasms
Cost-Benefit Analysis
Female
Humans
Letrozole
Nitriles
Piperazines
Pyridines
Receptors, Estrogen
Triazoles
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1007/s10549-017-4209-5
- PMID 28321586
- Persistent URL
- https://sonar.ch/global/documents/232374
Statistics
Document views: 20
File downloads:
- Full-text: 0